Cellectis
CLLS
#7233
Rank
โ‚น43.20 B
Marketcap
โ‚น416.22
Share price
-2.53%
Change (1 day)
150.81%
Change (1 year)

Revenue for Cellectis (CLLS)

Revenue in 2025 (TTM): โ‚น6.55 Billion

According to Cellectis's latest financial reports the company's current revenue (TTM ) is โ‚น6.78 Billion. In 2024 the company made a revenue of โ‚น3.56 Billion an increase over the revenue in the year 2023 that were of โ‚น62.85 Million. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Cellectis from 2015 to 2025

Annual revenue

Year Revenue Change
2025 (TTM) โ‚น6.55 B84.23%
2024 โ‚น3.56 B5565.07%
2023 โ‚น62.85 M-96.01%
2022 โ‚น1.57 B-63.02%
2021 โ‚น4.26 B-20.26%
2020 โ‚น5.34 B396.29%
2019 โ‚น1.07 B19.8%
2018 โ‚น0.89 B-43.93%
2017 โ‚น1.60 B-44.4%
2016 โ‚น2.88 B-20.57%
2015 โ‚น3.63 B

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
uniQure
QURE
โ‚น1.41 B-79.07%๐Ÿ‡ณ๐Ÿ‡ฑ Netherlands
Novavax
NVAX
โ‚น92.28 B 1,260.89%๐Ÿ‡บ๐Ÿ‡ธ USA
Regeneron Pharmaceuticals
REGN
โ‚น1.283 T 18,829.17%๐Ÿ‡บ๐Ÿ‡ธ USA
Flexion Therapeutics
FLXN
โ‚น9.04 B 33.39%๐Ÿ‡บ๐Ÿ‡ธ USA